The Trump administration is simultaneously gutting and expanding the nation's overdose prevention toolkit, creating a policy collision that has public health experts questioning the government's actual priorities.
In recent weeks, the administration has banned federal funding for fentanyl test strips while pledging support for naloxone, proposed cutting $10 billion from addiction and overdose prevention programs, and unveiled an ambitious National Drug Control Strategy aimed at expanding access to naloxone and treatment. The contradiction is stark: officials are willing to bankroll medication that reverses overdoses but not strips that prevent them in the first place.
The April decision by the Substance Abuse and Mental Health Services Administration to defund test strips that help users identify dangerous adulterants in their drug supply has alarmed researchers. Nabarun Dasgupta, director of the University of North Carolina's Opioid Data Lab, called the move "a win for the cartels," noting it strips away a critical tool for people to identify impure products.
The inconsistency runs deeper. In January, the CDC blocked "never use alone" messaging, a harm reduction tactic that ensures someone is present to administer naloxone in case of emergency. Now Samhsa is eliminating test strip funding while emphasizing naloxone support. The irony is unavoidable: the administration is rejecting prevention tools while championing rescue medications.
The policy confusion stems from a lack of coordination between government agencies. The White House's proposed budget cuts come from the Office of Management and Budget, while the more ambitious drug control strategy originates from the Office of National Drug Control Policy. Richard Baum, former acting director of the White House's national drug control policy, confirmed that the two proposals operate largely independent of each other.
The National Drug Control Strategy includes wastewater surveillance and technology expansion to track drug supplies. But Dasgupta finds this approach puzzling given the attack on test strips. While wastewater can offer broad signals about drug use patterns, it cannot capture the granular, hour-to-hour changes in street drug composition that users actually face. Some ultra-potent synthetic opioids like nitazines, which have surged as fentanyl supply tightens internationally, disappear in urine and show up poorly in wastewater at reliable levels.
Individual drug-checking tools offer precision medicine that wastewater surveillance cannot match. When users can test their supply, they have choices: they may refuse a dangerous batch, use more slowly, or use with others present. That behavioral shift matters. Maritza Perez Medina, director of federal affairs for the Drug Policy Alliance, stressed that test strips empower people to make safer decisions in real time.
The budget cuts present another obstacle to the drug strategy's implementation. If Congress approves the proposed $10 billion reduction, hospitals will close and addiction treatment availability will shrink, particularly through Medicaid cuts. The strategy cannot succeed in that environment.
Dasgupta described the overall approach as "kind of weak sauce," leaning on technology that was cutting edge a decade ago. More advanced mass spectrometry testing and individual drug-checking services align better with precision medicine. The administration, he argued, has access to better tools now.
The White House and the Office of National Drug Control Policy did not respond to requests for comment on the policy contradictions.
Author James Rodriguez: "You cannot claim to want fewer overdose deaths while simultaneously dismantling the tools that help people avoid them in the first place."
Comments